Guizhi Fuling Capsule ameliorates endometrial hyperplasia through promoting p62-Keap1-NRF2-mediated ferroptosis.

[1]  Ying Zhu,et al.  Guizhi Fuling Wan reduces autophagy of granulosa cell in Rats with polycystic ovary syndrome via restoring the PI3K/AKT/mTOR signaling pathway. , 2021, Journal of ethnopharmacology.

[2]  Yanling Xiao,et al.  Guizhi Fuling wan for chronic pelvic inflammatory disease protocol , 2020, Medicine.

[3]  Ying Zhu,et al.  Guizhi Fuling Wan, Chinese Herbal Medicine, Ameliorates Insulin Sensitivity in PCOS Model Rats With Insulin Resistance via Remodeling Intestinal Homeostasis , 2020, Frontiers in Endocrinology.

[4]  Xiaohua Song,et al.  Nrf2 and Ferroptosis: A New Research Direction for Neurodegenerative Diseases , 2020, Frontiers in Neuroscience.

[5]  H. Taylor,et al.  Endometriosis: The Role of Iron Overload and Ferroptosis , 2020, Reproductive Sciences.

[6]  Bei Sun,et al.  Ferroptosis: past, present and future , 2020, Cell Death & Disease.

[7]  I. Shih,et al.  The Origin and Pathogenesis of Endometriosis. , 2020, Annual review of pathology.

[8]  S. Salvador,et al.  Guideline No. 392-Classification and Management of Endometrial Hyperplasia. , 2019, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[9]  L. Insabato,et al.  Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta‐analysis , 2019, Acta obstetricia et gynecologica Scandinavica.

[10]  Antonio Cuadrado,et al.  Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases , 2019, Nature Reviews Drug Discovery.

[11]  B. Stockwell,et al.  Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease , 2017, Cell.

[12]  Liuting Zeng,et al.  A network pharmacology approach to investigate the pharmacological effects of Guizhi Fuling Wan on uterine fibroids , 2017, Experimental and therapeutic medicine.

[13]  M. Rauh,et al.  Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis , 2017, Oncogenesis.

[14]  Hongchuan Jin,et al.  Tamoxifen activates Nrf2-dependent SQSTM1 transcription to promote endometrial hyperplasia , 2017, Theranostics.

[15]  M. Arends,et al.  New concepts for an old problem: the diagnosis of endometrial hyperplasia , 2016, Human reproduction update.

[16]  W. Xiao,et al.  Traditional Chinese medicine Guizhi Fuling capsule used for therapy of dysmenorrhea via attenuating uterus contraction. , 2016, Journal of ethnopharmacology.

[17]  Zhenzhong Wang,et al.  Integrated identification, qualification and quantification strategy for pharmacokinetic profile study of Guizhi Fuling capsule in healthy volunteers , 2016, Scientific Reports.

[18]  H. Hsieh,et al.  Guizhi Fuling Wan as a Novel Agent for Intravesical Treatment for Bladder Cancer in a Mouse Model , 2016, Molecular medicine.

[19]  A. Dwivedi,et al.  Therapeutic options for management of endometrial hyperplasia , 2015, Journal of gynecologic oncology.

[20]  Donna D. Zhang,et al.  p62 links autophagy and Nrf2 signaling. , 2015, Free radical biology & medicine.

[21]  H. Inoue,et al.  Activation of Nrf2/Keap1 signaling and autophagy induction against oxidative stress in heart in iron deficiency , 2015, Bioscience, biotechnology, and biochemistry.

[22]  M. K. Kim,et al.  Conservative treatment for atypical endometrial hyperplasia: what is the most effective therapeutic method? , 2014, Journal of gynecologic oncology.

[23]  K. Terasawa,et al.  Identification of a Predictive Biomarker for the Beneficial Effect of Keishibukuryogan, a Kampo (Japanese Traditional) Medicine, on Patients with Climacteric Syndrome , 2014, Evidence-based complementary and alternative medicine : eCAM.

[24]  W. Hurd,et al.  Diagnosis and management of endometrial hyperplasia. , 2012, Journal of minimally invasive gynecology.

[25]  M. R. Lamprecht,et al.  Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death , 2012, Cell.

[26]  Rochelle L. Garcia,et al.  Complex Hyperplasia With and Without Atypia: Clinical Outcomes and Implications of Progestin Therapy , 2010, Obstetrics and gynecology.

[27]  F. Demirkıran,et al.  The effect of long‐term use of progesterone therapy on proliferation and apoptosis in simple endometrial hyperplasia without atypia , 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[28]  Mark Hannink,et al.  Keap1 Is a Redox-Regulated Substrate Adaptor Protein for a Cul3-Dependent Ubiquitin Ligase Complex , 2004, Molecular and Cellular Biology.

[29]  Young-Chae Chang,et al.  Effects of the Geiji‐Bokryung‐Hwan on Carrageenan‐Induced Inflammation in Mice and Cyclooxygenase‐2 in Hepatoma Cells of HepG2 and Hep3B , 2004, Immunopharmacology and immunotoxicology.

[30]  R. Kurman,et al.  The behavior of endometrial hyperplasia. A long‐term study of “untreated” hyperplasia in 170 patients , 1985 .